Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - PDL BIOPHARMA, INC. | pdli-2018063010qdoc.htm |
| EX-32.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2018063010qex321.htm |
| EX-31.2 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2018063010qex312.htm |
| EX-31.1 - CERTIFICATION - PDL BIOPHARMA, INC. | pdli-2018063010qex311.htm |
| EX-10.2 - AMENDMENT NO. 1 TO ROYALTY PURCHASE AND SALE AGREEMENT - PDL BIOPHARMA, INC. | pdli-2018063010qex102.htm |
| EX-10.1 - 2018 ANNUAL BONUS PLAN - PDL BIOPHARMA, INC. | pdli-2018063010qex101.htm |
Exhibit 12.1
PDL BIOPHARMA, INC.
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Unaudited)
(Amount in thousands, except for ratios)
For the Six Months Ended June 30, 2018 | ||||||||||||||||||||||||
2013 | 2014 | 2015 | 2016 | 2017 | ||||||||||||||||||||
Earnings: | ||||||||||||||||||||||||
Income (loss) before income taxes | $ | 401,876 | $ | 501,272 | $ | 530,138 | $ | 109,370 | $ | 184,527 | $ | (123,940 | ) | |||||||||||
Add: fixed charges | 24,931 | 39,274 | 27,123 | 18,330 | 20,507 | 6,604 | ||||||||||||||||||
Earnings | $ | 426,807 | $ | 540,546 | $ | 557,261 | $ | 127,700 | $ | 205,034 | $ | (117,336 | ) | |||||||||||
Fixed Charges: | ||||||||||||||||||||||||
Interest expense1 | $ | 24,871 | $ | 39,211 | $ | 27,059 | $ | 18,267 | $ | 20,221 | $ | 6,396 | ||||||||||||
Estimated interest portion of rent expense2 | 60 | 63 | 64 | 63 | 286 | 208 | ||||||||||||||||||
Fixed charges | $ | 24,931 | $ | 39,274 | $ | 27,123 | $ | 18,330 | $ | 20,507 | $ | 6,604 | ||||||||||||
Ratio of earnings to fixed charges | 17.12 | 13.76 | 20.55 | 6.97 | 10.00 | (17.77 | ) | |||||||||||||||||
_____________________________________
1 Interest expense includes amortization of debt discount and expenses.
2 Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.